Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Nebraska Only)
Defines medical necessity and noncoverage for various electrical stimulation modalities for Nebraska members, including TENS, FES, NMES, and several percutaneous and implanted neurostimulation therapies.
Policy Summary
PayerUnitedHealthcare
PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Nebraska Only)
Policy CodePolicy CS036NE.U
Change TypeMinor/technical — no material clinical changes
Effective DateMay 1, 2026
Next Review DateN/A
Key ActionProvide prior-authorizing documentation of prior conservative therapy and trial-level evidence when requesting coverage for implanted neuromodulation or nonstandard NMES/FES indications.
No material clinical or coverage changes in this revision.
NE onlypolicy application
11FES criteria items
~12modalities listed unproven
>=10referenced codes
20+studies cited (selected)
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
FES coverage criteria: Demonstration of intact lower motor units (L1 and below) (both muscle and peripheral nerves)
FES coverage criteria: Muscle and joint stability for weight-bearing at upper and lower extremities that can demonstrate balance and control to maintain an upright support posture independently
FES coverage criteria: Demonstration of brisk muscle contraction
FES coverage criteria: Demonstration of sensory perception sufficient for muscle contraction
FES coverage criteria: Demonstration of a high level of motivation, commitment, and cognitive ability for device use
FES coverage criteria: Ability to transfer independently
FES coverage criteria: Demonstration of independent standing tolerance for at least 3 minutes>= 3 minutes
FES coverage criteria: Demonstration of hand and finger function to manipulate controls
FES coverage criteria: Post recovery from SCI and restorative surgery of at least 6 months>= 6 months
FES coverage criteria: Absence of hip and knee degenerative disease
FES coverage criteria: Absence of history of long bone fracture secondary to osteoporosis
inv-02: FES and neuromuscular electrical stimulation (evidence summary)
Evidence summaries for FES and other modalities with mixed quality:
FES evidence summary: FES has demonstrated improvements in muscle strength, aerobic capacity, and respiratory outcomes in some RCTs and systematic reviews for spinal cord injury and other neurologic conditions, but overall evidence is heterogeneous with many small studies and methodological limitations.
See Hayes and recent systematic reviews for details
inv-03: Implanted neurostimulation
Implanted peripheral stimulation modalities:
PNS/Restorative neurostimulation description: PNS and restorative neurostimulation are implantable therapies targeting peripheral nerves or the multifidus muscle for pain or functional rehabilitation; examples include StimRouter, SPRINT, Freedom, and ReActiv8.
No specific coverage criteria provided in this excerpt; see device-specific sections
inv-04: Evidence considerations for coverage decisions
Evidence-based considerations and implied coverage stance based on the literature summarized
General evidence considerations: Consider disease phase (acute/subacute vs chronic), assistive versus rehabilitative intent, device type, and study quality; the overall evidence base is low-to-moderate quality with inconsistent functional or quality-of-life benefits.
Hayes and ECRI assessments note small sample sizes, heterogeneity, and limited follow-up
inv-05: Evidence contexts where NMES/FES may be beneficial
Evidence summaries and contexts where NMES/FES showed benefit or mixed results:
Poststroke upper limb FES: Meta-analyses report mixed but sometimes positive effects on motor outcomes (FMA, Box and Block, AROM, Barthel Index) with low-quality evidence and heterogeneity; optimal parameters and long-term efficacy are unclear.
CCFES may show superiority to cyclic NMES in some trials
FES for foot drop (stroke and MS): FES combined with supervised exercise improved gait speed versus exercise alone; evidence quality is low and comparisons with AFOs are mixed for stroke and MS populations.
Hayes HTA concluded low-quality evidence
FES/NMES in heart failure: Systematic reviews of RCTs in CHF show improvements in peak VO2, 6-minute walk distance, and QOL with FES vs control, though conventional exercise often yields greater improvements.
6-week training programs reported in RCTs
inv-06: Contexts with positive/limited evidence
Evidence-based findings and contexts where NMES showed benefit in trials
Musculoskeletal postoperative recovery: Trials reported NMES reduced early postoperative pain during mobilization after THR/TKA, decreased limb edema, and increased femoral vein peak velocity (potential DVT prophylaxis), though effects were often short-term and sample sizes small.studies small and short-term
See THR and ACL studies for specifics
Strength preservation and rehabilitation: Home-based NMES programs prevented knee extensor weakness after ACL reconstruction and improved residual limb strength post-amputation; pediatric NMES improved muscle volume and strength in CP in short-term trials.varied durations (4–48 weeks)
Long-term carryover inconsistent
Poststroke applications: Systematic reviews indicate NMES plus conventional therapy can improve swallowing function and ADLs after stroke; benefits may be greater in subacute stage and severe paresis.
inv-07: Evidence summaries by indication
Coverage stance and conditional findings summarized from systematic reviews, RCTs, and guidelines in this segment:
Stroke — Activities of daily living (ADL): Pooled analyses show a positive effect of NMES on ADLs post-stroke (SMD ~0.41) with subgroup benefits when applied in the subacute stage and to the upper extremity; evidence limited by risk of bias.
See meta-analyses of 20 RCTs
Stroke — Functional motor ability and manual dexterity: Overall mixed findings; CCFES showed greater improvement than cNMES in some RCTs for manual dexterity, especially in moderate impairment and <2 years poststroke.
Translatability to broader practice unestablished
Poststroke dysphagia: NMES combined with conventional swallowing therapy may improve swallowing function and QOL, but evidence is heterogeneous; NICE advises use only with special governance or research arrangements.
Document governance per NICE if used
inv-08: Evidence-based coverage considerations
Coverage considerations based on evidence summaries in this section:
Knee osteoarthritis (IFT): IFT may provide short-term pain and function improvement in some RCTs and meta-analyses but evidence is heterogeneous and NICE recommends against routine offering for OA; require documentation of expected benefit and standardized protocol when considered.
Small trials and variable parameters limit conclusions
Postoperative and fracture rehabilitation (IFT/MENS): RCTs often show no significant additive benefit of IFT/MENS when added to standard rehabilitation; transient reductions in analgesic use have been reported but sustained benefits are inconsistent.
High-quality supportive documentation required if claimed
Microcurrent therapy: MENS/MET evidence is limited to small RCTs and pilot studies with mixed findings; insufficient high-quality evidence to broadly support coverage for most indications.
Evidence summary and implied coverage stance based on quality and outcomes
General evidence characteristics: Most RCTs/reviews are small, use heterogeneous protocols, and have short follow-up; some studies report immediate or short-term benefits but long-term effects are unproven.
GRADE assessments often low or very low
Situations with positive short-term evidence: Selected trials report short-term reductions in pain or improved function (eg, MENS for acute knee pain; PENS for ACL rehab; auricular PENFS reducing opioid use post-TKA), but these findings are context- and protocol-dependent.
Typically small, short-duration studies
Uncertainty and guideline cautions: Guidelines (NICE, ACP) and HTA bodies note low-quality evidence and often recommend against routine use for several electrotherapies (eg, PENS for LBP; IFT for OA), supporting conservative-first approaches.
Document prior conservative therapy
inv-10: PENFS — evidence-based use cases
Evidence supports potential benefit in specific short-term settings but is limited; include criteria logic reflecting study populations and gaps.
PENFS candidate criteria (derived from evidence): Patient characteristics mirroring studies: adults undergoing certain surgeries (eg, TKA, laparoscopic procedures) or pediatric patients with DGBIs; device applied in immediate postoperative recovery or as multi-week therapy; exclude chronic opioid dependence, neuromuscular deficits, bleeding disorders, anticoagulation, pregnancy, pacemaker/implantable device; document prior conservative therapies where applicable for chronic conditions.
Based on pilot RCTs and registries
inv-11: PNS — evidence considerations and candidate selection
PNS has shown clinically meaningful improvements in selected trials but evidence is heterogeneous; criteria should require careful selection and documentation.
PNS candidate criteria (derived from evidence): Adults with chronic neuropathic pain refractory to conventional medical management; pain localized to a peripheral nerve distribution; documentation of prior conservative therapies and response; consider temporary/ trial PNS (eg, up to 60 days) before permanent implantation; informed consent regarding limited long-term comparative evidence and device-specific risks.
Covered when supported by guideline-based criteria and evidence
ASIPP-based implantation criteria: Implantable PNS for moderate to severe chronic pain refractory to two or more conservative treatments; may follow a temporary 60-day PNS trial or selective lumbar medial branch stimulation without a trial per ASIPP guidance.two or more conservative treatments failed
Evidence level: fair; strength: moderate
inv-13: Evidence strength and limitations
Evidence considerations affecting coverage
Evidence from RCTs and case series: Some RCTs and prospective series report clinically meaningful pain and functional improvements (eg, Goree et al., Gilmore et al.), but many studies are small, heterogeneous, and limited by methodological issues, producing low to moderate certainty evidence.
Document trial parameters and follow-up
inv-14: PEMF — general evidence-based coverage considerations
Evidence summary and implications for coverage decisions
PEMF evidence summary: PEMF shows some short-term pain and function benefits in OA and non-specific LBP across small RCTs and systematic reviews, but heterogeneity of parameters, small samples, and short follow-up limit certainty.
Further high-quality trials needed to define optimal settings and long-term effects
inv-15: PEMF for acute fracture healing
Covered when ALL of the following are met
Fracture healing: RCT evidence does not demonstrate consistent, statistically significant improvement in fracture union or clinically consistent benefit with PEMF; routine use for acute fracture healing is not supported.
Picelli et al. systematic review found no consistent benefit across 3 RCTs
inv-16: PEMF for osteoarthritis (knee and other joints)
Evidence-informed considerations
OA pain and function: Systematic reviews and RCTs report short-term pain reduction and some functional improvement for knee OA with PEMF; benefits are more consistent with 4–6 week regimens but quality of evidence is low to moderate and generalizability is limited.
AAOS graded recommendation: limited
inv-17: PEMF after knee arthroplasty
RCT evidence summary
Post-UKA clinical outcomes: A single RCT reported improved pain, Oxford Knee Score, reduced NSAID use, and reduced swelling up to 36 months with PEMF versus control, though limitations include small size and lack of placebo control; interpret cautiously as adjunctive therapy.
Document device regimen and medication use when claiming benefit
inv-18: PEMF combined with other therapies
Study-level findings
Combination therapies: Trials of PEMF combined with exercise or PRP show mixed results: some report added benefit (eg PRP+PEMF in early knee OA), others show no advantage over exercise alone; heterogenous protocols and small samples limit conclusions.
Consider conservative therapy response before adding PEMF
inv-19: PEMF for MS-related fatigue and function
Not supported by RCT evidence
MS fatigue: Low-frequency PEMF showed no benefit over placebo for fatigue, walking performance, depression, or QOL in relapsing-remitting MS in an RCT; current evidence does not support PEMF for MS-related fatigue.
Not recommended based on current evidence
inv-20: Restorative neurostimulation (ReActiv8) for refractory mechanical CLBP
Covered when ALL of the following are met (based on trial eligibility and outcomes)
Candidate selection: Patients with mechanical chronic low back pain associated with multifidus dysfunction, chronic symptoms refractory to conservative and interventional therapies, and baseline ODI ~30–60 and NRS 6–9 were those enrolled in pivotal trials.
Prior failure of conservative care expected (>90 days)
Expected benefit: Restorative neurostimulation produced clinically meaningful improvements in ODI and NRS vs OMM at 1 year in randomized trials; device-related adverse events were infrequent and mostly minor.
Consider prior authorization and trial-like documentation when requesting coverage
Evidence and trial eligibility characteristics for restorative neurostimulation (informational; not explicit coverage criteria in this excerpt):
ReActiv8 trial-like eligibility: Participant has refractory mechanical CLBP with impaired multifidus control; continued pain despite ≥90 days of medical management and at least one attempt of physical therapy; evaluated in specialized centers as in trials.as described in trial reports
Document baseline VAS/NRS, ODI, EQ-5D and prior conservative therapies
inv-22: Scrambler therapy: protocol observations
Scrambler therapy evidence summary and typical treatment protocols observed:
Scrambler therapy typical protocol: Treatment sessions are typically 30–50 minutes each over ~10 working days (about 10 sessions); outcomes are assessed immediately post-treatment and up to 3 months in trials.10 sessions / 30–50 minutes
Protocol consistent across multiple small RCTs
inv-23: Evidence and guideline-based coverage considerations
Evidence synthesis and guideline conclusions for scrambler therapy and translingual stimulation
Scrambler therapy evidence summary: Randomized and nonrandomized studies report potential short-term analgesic benefit for neuropathic pain (including CIPN and burn-related neuropathic pain) but systematic reviews characterize the evidence as low or very low quality and call for larger, well-designed RCTs.
Hayes and other reviews note low certainty
Guideline stance for CIPN: ASCO: no recommendation outside clinical trials; ESMO/EONS/EANO: not recommended (grade D) for CIPN due to inconsistent outcomes in small RCTs.
Prior authorization and trial enrollment documentation advised if requested
Translingual stimulation evidence summary: PoNS/TLS combined with targeted physical therapy showed improvements in balance and gait in small trials, but many studies show improvements in both active and control arms; further sham-controlled trials are needed to isolate device-specific effects.
Multicenter RCTs exist but generalizability limited
inv-24: Device-specific approved indications
Coverage aligned with FDA-approved indications when specified
ReActiv8 PMA indication: Device indicated for bilateral stimulation of the L2 medial branch as an aid in management of intractable chronic low back pain associated with multifidus dysfunction in adults who have failed therapy including medications and physical therapy and are not surgical candidates; support with imaging or physiologic testing as evidence of multifidus dysfunction.
Follow PMA labeling for patient selection
This policy identifies multiple electrical stimulation modalities evaluated in the evidence base. Examples include Functional Electrical Stimulation (FES), Neuromuscular Electrical Stimulation (NMES), Transcutaneous Electrical Nerve Stimulation (TENS), Percutaneous Electrical Nerve Stimulation (PENS/PNT), Percutaneous Electrical Nerve Field Stimulation (PENFS), Percutaneous Peripheral Nerve Stimulation (PNS), Peripheral Nerve Field/Subcutaneous Field Stimulation (PNFS/PSFS), Pulsed Electromagnetic Field (PEMF) stimulation, restorative neurostimulation, scrambler therapy, and translingual stimulation (PoNS/TLS) as described in the literature and device sections of this policy.
Within coverage criteria the policy specifies that FES may be medically necessary for selected SCI-related ambulation and rehabilitation uses when detailed clinical criteria are met (see FES criteria including intact lower motor units, functional readiness, transfer ability, manipulation of controls, and thresholds such as post-recovery >= 6 months and independent standing tolerance >= 3 minutes). Evidence summaries note variable effectiveness across indications and study quality limitations.
Several modalities are identified in the policy as lacking sufficient high-quality evidence for routine coverage and are listed as unproven or not medically necessary in the exclusions and not-covered sections; these explicitly include Interferential therapy (IFT), Microcurrent electrical nerve stimulation (MENS), PENS/PNT, PENFS, general PNS (except where specific indications or other policies apply), PNFS/PSFS, PEMF, restorative neurostimulation, scrambler therapy, and translingual stimulation for gait rehabilitation.
The policy notes that evidence for home-based FES for rehabilitation following spinal cord injury is limited and inconclusive. Hayes’ health technology assessment and systematic reviews identified small, heterogeneous studies with variable protocols and follow-up, and concluded that while FES shows promise for improving strength and some functional outcomes, the overall quality of the evidence is low and home-based FES for SCI rehabilitation lacks sufficient peer-reviewed support to recommend routine coverage without stronger trial evidence and clear documentation of patient-level candidacy.
When coverage is considered for FES in SCI populations, the policy emphasizes trial-level eligibility and outcome measures used in published studies and HTAs; documentation should mirror trial-like criteria (device/protocol, functional baseline, and follow-up measures) to support medical necessity requests.
Procedure, Supply, and Product Codes
Procedure CPT Codes (selected)CPT
0278T
Transcutaneous electrical modulation pain reprocessing (e.g., scrambler therapy), each treatment session (includes placement of electrodes).
0783T
Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment.
63650
Percutaneous implantation of neurostimulator electrode array, epidural.
63655
Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural.
63663
Revision including replacement, when performed, of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed.
63664
Revision including replacement, when performed, of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed.
63685
Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array.
64597
Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; each additional electrode array.
64598
Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator.
64999
Unlisted procedure, nervous system.
HCPCS / Supply CodesHCPCS
A4438
Adhesive clip applied to the skin to secure external electrical nerve stimulator controller, each.
A4543
Supplies for transcutaneous electrical nerve stimulator, for nerves in the auricular region, per month.
A4544
Electrode for external lower extremity nerve stimulator for restless legs syndrome.
A4556
Electrodes (e.g., apnea monitor), per pair.
A4557
Lead wires (e.g., apnea monitor), per pair.
A4593
Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, controller.
A4594
Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece, each.
A4595
Electrical stimulator supplies, 2 lead, per month, (e.g., TENS, NMES).
Transcutaneous electrical nerve stimulator, for nerves in the auricular region.
1–10 of 28
1/3
HCPCS E0770 — PDAC-verified devicesmixed
E0770 (verified devices)
Deluxe Digital Electronic Muscle Stimulator (Drive Medical); NESS L300 and H200 devices (Bioness); Odstock ODFS Pace FES System (Odstock Medical/Boston Brace); WalkAide (Innovative Neurotronics).
No explicit codes provided in this sectionmixed
No codes listed
FDA product codes referencedmixed
LIH
product code for interferential therapy devices
ILX
product code for pulsed electromagnetic field stimulation devices
NHI
product code for percutaneous electrical nerve stimulator devices
GZB
product code for peripheral nerve stimulation devices
GZF
product code for peripheral nerve stimulation devices
QHH
product code for IB-Stim percutaneous electrical nerve field stimulation (DEN180057)
PZR
alternate product code for IB-Stim (per document)
QLK
product code for ReActiv8 Implantable Neurostimulation System (PMA)
GZJ
product code used for TENS/Scrambler devices
BWK
product code mentioned for percutaneous electrical nerve stimulators (Class II)
1–10 of 13
1/2
inv-60: Post-recovery interval after SCI and restorative surgery for FES
Post-recovery interval>= 6 months
Indication contextPost recovery from SCI and restorative surgery
Supporting requirementDemonstration of intact lower motor units (L1 and below)
Related exclusionFES not medically necessary for indications other than specified SCI ambulation criteria
inv-61: Independent standing tolerance for FES candidacy
Independent standing tolerance
Prior Authorization, Documentation, and Operational Guidance
Documentation Required
Medical Record Documentation
Medical records must fully support medical necessity for requested neuromodulation and electrical stimulation services. Documentation should include relevant medical history, physical exam, diagnostic test results, prior conservative therapies and their durations, trial-phase results (if applicable), device details, and follow-up assessments. Lack of adequate documentation may result in denial or request for additional information.
Include prior conservative treatments and dates (PT, medications, injections).
Document objective findings and functional measures used to demonstrate impairment and treatment response.
When a trial stimulation is performed, include trial parameters, duration, and measured clinical benefit.
Billing Rule
Required Prior Therapies and Readiness
inv-164: Functional and neurologic readiness demonstrated (see FES criteria list)
Conservative-treatment expectations informing candidate selection and authorization:
Conservative-first approach: Document prior conservative therapies and trial responses before considering device-based therapies; many guidelines and trials require trials of exercise/physical therapy and medical management (often ≥90 days for restorative neurostimulation and failure of two or more conservative treatments for implantable PNS per ASIPP).≥ 90 days for restorative neurostimulation; failure of ≥2 conservative treatments for implantable PNS
Document duration and supervised nature of prior rehab per trial protocols
FES-specific conservative considerations: When clinically appropriate, document trial of conservative measures such as ankle-foot orthosis (AFO) and conventional PT prior to durable FES for foot drop or ambulation rehabilitation.
Comparative trials frequently used AFO as comparator
Treatment Frequency, Trial Durations, and Typical Regimens
inv-179: FES training for CHF (Kadoglou et al.)
Training program duration (CHF RCT)6-week FES training program described in Kadoglou et al. (n=120)
PopulationParticipants stable with CHF (NYHA II/III) in RCT
Reported outcomesReduced heart-failure–related hospitalizations in FES group
Follow-upMedian follow-up ~383 days for hospitalization/mortality endpoints
inv-180: NMES after total hip replacement
NMES sessions (THR feasibility study)Up to 20 sessions over 5 days; minimum 30 minutes per session
Setting
Imaging and Procedural Guidance Expectations
Note
Unspecified imaging requirements
No explicit imaging requirements are listed in this segment; document pertinent diagnostics as clinically indicated and per device trial protocols.
Documentation Required
Implantation of PNS/restorative neurostimulation (implied imaging guidance)
Implantation procedures for PNS and restorative neurostimulation typically utilize image guidance during lead placement; include procedural imaging or fluoroscopic guidance notes in the record when applicable.
Document intraoperative imaging modality used (eg, fluoroscopy, ultrasound) and target nerve/landmark descriptions.
Include operative report and device model details.
Documentation Required
FES for post-stroke rehabilitation — imaging as clinically indicated
For FES used in post‑stroke rehabilitation, obtain and document stroke confirmation imaging (CT/MRI) as clinically indicated and include timing since stroke and severity of paresis in the record.
Modalities Considered Not Medically Necessary / Insufficient Evidence
Modalities explicitly listed in the policy as not supported by sufficient evidence and therefore not covered (where not otherwise specified) include: Interferential therapy (IFT), Microcurrent electrical nerve stimulation (MENS), Percutaneous electrical nerve stimulation (PENS/PNT), Percutaneous electrical nerve field stimulation (PENFS), Percutaneous peripheral nerve stimulation (PNS) (general), Peripheral subcutaneous field stimulation (PSFS/PNFS), Pulsed electromagnetic field (PEMF) stimulation, restorative neurostimulation, scrambler therapy, and translingual stimulation for gait rehabilitation.
The policy describes that current evidence is insufficient to support routine coverage of home-based FES for rehabilitation following SCI. Hayes’ HTA and the systematic literature search found small, heterogeneous studies with limited quality and follow-up; consequently the policy characterizes this indication as having insufficient/unclear support absent more robust peer-reviewed evidence.
Device-specific assessments may be inconclusive. For example, an ECRI clinical evidence assessment for the MyndMove FES system concluded the published evidence was too limited and at high risk of bias (very small, single-center, unblinded trials), yielding an inconclusive determination for efficacy in post-stroke adults and supporting a noncoverage or cautious stance until larger, higher-quality RCTs are available.
Several modalities are reiterated across the exclusions and not-covered lists; these duplicate entries underscore the policy’s consistent position that certain transcutaneous, percutaneous, and electromagnetic modalities lack sufficient evidence for routine coverage. Notably, IFT, MENS, PENS/PNT, PENFS, general PNS (where not specifically indicated), PNFS/PSFS, PEMF, restorative neurostimulation, scrambler therapy, and translingual stimulation for gait rehabilitation appear multiple times as unproven/not medically necessary in the policy text and associated guideline references.
Definitions and Terminology
inv-124: FES definition
DefinitionFES: direct application of electric current to intact nerve fibers to cause involuntary but purposeful muscle contraction enabling functional activities (eg, standing, ambulation)
ApplicationElectrodes may be surface or surgically implanted; used for therapeutic (exercise) or functional (assistive) goals
DefinitionNMES: transcutaneous electrical currents cause muscle contractions to promote reinnervation, prevent disuse atrophy, relax spasms, and promote voluntary muscle control
DeliveryApplied transcutaneously to evoke contractions; distinct from TENS which targets sensory nerves
Background, Evidence Sources, and References
Electrical stimulation modalities use different targets and mechanisms: FES applies coordinated currents to intact peripheral nerves to evoke purposeful muscle contractions for functional tasks; NMES evokes muscle contractions to prevent atrophy and support rehabilitation; PENS employs percutaneous needle electrodes for analgesia; PNS/PNFS place leads near peripheral nerves or subcutaneous fields for pain modulation; PEMF applies pulsed electromagnetic fields to tissues with proposed effects on healing and inflammation; restorative neurostimulation targets the multifidus to rehabilitate neuromuscular control in chronic low back pain; and scrambler therapy and translingual stimulation (PoNS) are noninvasive neuromodulation approaches delivering patterned surface or lingual stimulation paired with therapy.
Mechanisms differ across modalities (muscle activation for functional assistance or rehabilitation, nerve-targeted signal modulation for analgesia, or electromagnetic field effects for tissue repair), which the policy highlights when linking indications, trial populations, and the strength of evidence behind each technique.
Key references supporting the evidence summaries include systematic reviews, randomized controlled trials, HTAs, and device-specific assessments cited throughout the policy (examples: Eraifej et al. for upper-limb poststroke FES; da Cunha et al. for foot-drop FES; Hayes and ECRI technology assessments; and multiple RCTs and reviews enumerated in the references section). These sources underpin the policy’s distinctions between modalities with limited positive findings and those judged unproven.
Providers should consult the referenced trials and HTAs cited in the policy when preparing documentation to support coverage requests, as the policy’s evidence statements and device judgments are grounded in these peer-reviewed sources.
Definitions and conceptual distinctions cited in the background include: PNS — implantation or percutaneous placement of electrode(s) near a peripheral nerve to deliver impulses that disrupt pain transmission; and FES — application of electrical stimulation to intact nerve or muscle to generate purposeful functional movements for rehabilitation. These definitions are used throughout the policy to differentiate assistive versus rehabilitative applications and to align device-specific indications with the evidence base.
Policy Summary
PayerUnitedHealthcare
PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Nebraska Only)
Policy CodePolicy CS036NE.U
Change TypeMinor/technical — no material clinical changes
Effective DateMay 1, 2026
Next Review DateN/A
Key ActionProvide prior-authorizing documentation of prior conservative therapy and trial-level evidence when requesting coverage for implanted neuromodulation or nonstandard NMES/FES indications.
NMES in musculoskeletal/postoperative rehab: RCTs report NMES added to conventional rehabilitation can reduce early postoperative pain, increase quadriceps strength after joint replacement/ACL reconstruction, and may increase femoral venous flow after THR; study limitations include small sizes and heterogeneity.
Protocols vary widely across trials
benefits more apparent in subacute stage
NICE recommends governance/research arrangements for dysphagia
Pediatric cerebral palsy: Multiple RCTs and reviews indicate NMES can improve muscle volume, strength, gait, and reduce spasticity in children with spastic CP, but protocols and dosing are heterogeneous and optimal parameters undefined.evidence mostly from small trials
Further research recommended
COPD — NMES: NMES as an adjunct to pulmonary rehabilitation may improve exercise capacity, quadriceps strength, and QOL in some trials, but evidence quality is low to very low and NMES is not a substitute for pulmonary rehab.
Document prior or concurrent pulmonary rehabilitation
Chronic low back pain — transcutaneous electrotherapies: Systematic reviews find inconsistent benefits for TENS and IFT; IFT showed short-term benefits in some trials but NICE/ACP guidance does not support routine use for OA or chronic primary pain.
Effects largely short-term
Knee osteoarthritis — IFT: Network/meta-analyses report modest or inconsistent short-term pain and function benefits for IFT in knee OA; heterogeneity and guideline cautions limit generalizability.
Require standardized protocol and documentation
>= 3 minutes
Functional requirementMuscle and joint stability to maintain upright support posture independently
Transfer abilityAbility to transfer independently
Control requirementDemonstration of hand and finger function to manipulate controls
Applicable Codes — Reference Only
Applicable procedure and supply codes are provided for reference only and do not by themselves establish coverage. Providers should not assume that inclusion implies prior authorization is required or payment guaranteed.
Prior authorization requirements are not explicitly specified in these source segments. Where plan or state contract rules apply, providers should verify UnitedHealthcare prior authorization policies for implanted neurostimulation devices, restorative neurostimulation (e.g., ReActiv8), and selected device-specific programs before scheduling procedures.
No procedural or prior authorization requirement is stated within these chunks.
Prior authorization may still be required by payer/provider contract — confirm via insurer portal or policy lookup.
Note
Adjunctive Use with Rehabilitation
Many NMES and FES studies were conducted as adjuncts to standard rehabilitation rather than as stand-alone treatments. Reviews and guidelines commonly expect NMES/FES to be used in combination with conventional therapy; documentation should reflect adjunctive use and concurrent rehabilitation activities.
Document the concurrent rehabilitation program (type, frequency, duration) when NMES/FES is used as an adjunct.
Studies showing benefit often combined NMES/FES with supervised exercise or PT.
Denial Risk
Explantation and Device-Related Risks
Some studies of implantable PNS report device explantation due to insufficient benefit or complications. Providers should counsel patients on explantation risk and document trial-phase response and shared decision-making.
Report examples: explantation for insufficient benefit and for wound infection were observed in retrospective series.
Document informed consent including potential for explantation and device-related complications.
Note
Guideline Expectation: Conservative-First and Trial-Based Approach
Guideline-based expectations exist for implantable PNS: many societies recommend a conservative-first approach and evidence often supports implantable systems only after failure of multiple conservative treatments and, when applicable, a successful trial.
ASIPP supports implantable PNS after failure of two or more conservative treatments (see ASIPP guidance).
Hayes and Ontario Health note limited/low-quality evidence and recommend careful patient selection and further trials.
Documentation Required
Governance / Research Requirement for Select Indications
Some clinical practice guidelines and technology assessments recommend research governance or restricted use for specific indications (e.g., NMES for dysphagia) until higher-quality evidence is available. Use under special arrangements (audit, consent, research) may be appropriate.
NICE recommends use of NMES for dysphagia only with clinical governance and audit or within research.
Document protocol, consent, and outcome monitoring when using therapies under special arrangements.
Denial Risk
Coverage Determinations Depend on Evidence and Documentation
Absence of explicit authorization or denial triggers in these chunks means coverage decisions may depend on evidence sufficiency and plan-specific criteria. Insufficient or low-quality evidence cited in reviews may lead to denial if clinical criteria are unmet.
Evidence insufficiency noted across modalities (scrambler therapy, PNS, IFT) could prompt noncoverage in absence of documented medical necessity.
When evidence is limited, supply thorough documentation of prior treatments, objective impairment, and rationale for device selection.
Prior Authorization
Prior Authorization Recommended When Claiming Clinical Benefit
When claiming clinical benefit for a device-based therapy (trial or implant), prior authorization is recommended by reviewers and device-assessment bodies to ensure appropriate patient selection, device indication, and documentation are in place.
Although not specified within these chunks, prior authorization is commonly recommended for implanted restorative neurostimulation (ReActiv8) and other implantable neuromodulation systems.
Provide trial results, prior conservative therapy documentation, and device-specific indications at authorization submission.
PNS/PENFS trial requirement: Consider a temporary percutaneous PNS trial (commonly ~60 days) before permanent implantation when supported by evidence and guideline recommendations; document trial stimulation response and target nerve localization.~60 days trial typical
Trials and RCTs used temporary systems in several studies
Applied post–total hip replacement in feasibility RCT (geko device)
Outcomes measuredVAS pain on mobilization (postop days 1,3,5), calf/thigh circumference
Study limitationsOpen-label, single-center, small sample (n=60)
inv-181: NMES trial protocol variability
Protocol variabilityTrial protocols varied widely (daily sessions for weeks to multiple sessions over days)
Reported durationsExamples include 6-week programs and single-session studies; heterogenous by indication
ImplicationNo standardized NMES dosing established across indications
inv-182: PENS / MENS session counts and variability
Typical session countsMost PENS/MENS studies used few sessions (range 1–16)
Common indicationsAcute postoperative pain, ACL rehabilitation, MSK pain
Evidence limitationSmall trials and short follow-up preclude standard frequency recommendation
inv-183: PENFS/PNS temporary lead therapy durations
Typical temporary lead durationsTemporary systems typically applied for 5–60 days in studies
Auricular PENFS exampleNSS-2 Bridge applied for days (e.g., 5 days post-TKA in pilot RCT)
Study limitationsSmall sample sizes and short-term follow-up; patient selection varied
Implant timing and regimenRestorative neurostimulation implantation performed after failure of conservative/interventional therapies (often >90 days)
Therapy activationStimulation programs in trials: e.g., twice-daily sessions of specified minutes (trial-dependent)
Follow-up expectationsLongitudinal follow-up reported up to 4–5 years in pivotal cohorts
Provide CT/MRI stroke confirmation and time since stroke (acute/subacute/chronic) when relevant to FES candidacy.
Record Brunnstrom stage, Modified Ashworth Scale, and functional baseline metrics.
Note
NMES for muscle hypertrophy — MRI used in trials (not an authorization requirement)
Trials of NMES for muscle hypertrophy frequently used MRI as an outcome measure; MRI is not required for authorization but may be submitted as objective outcome evidence when available.
If MRI muscle volume measures were obtained in treatment, include pre/post images or summarized results to support response.
Documentation Required
NMES/CCFES for poststroke upper extremity — imaging not routinely required
NMES/CCFES poststroke upper‑extremity trials documented timing since stroke and severity of paresis as modifiers of effect; no routine imaging requirement is specified — include clinical timing and severity in documentation.
Document time since stroke, impairment severity, and functional measures (FMA‑UE, Box and Block) in the record.
Imaging only as clinically indicated for diagnosis confirmation.
Note
MENS/MCT outcome assessment — imaging not required
Outcome assessments for MENS/MCT studies did not require routine imaging; include ultrasound or other objective outcome measures only if used in the clinical protocol.
Document ultrasound findings if used as an outcome (eg, effusion reduction) but not required for authorization.
Documentation Required
PENS / MENS — ultrasound guidance when used in study protocols
Some PENS study protocols used ultrasound guidance for needle placement; if ultrasound guidance was used clinically, document it in the procedure note.
Include ultrasound guidance details (target nerve, needle size) in procedural documentation when applicable.
Documentation Required
PNS lead placement — procedural guidance documentation
PNS lead placement studies described procedural guidance and anatomic targets; include target nerve(s) and approach in operative/procedure notes to support the claim.
Document targeted nerves (eg, femoral, sciatic, saphenous, suprascapular) and imaging or guidance modality used.
Include lead depth, laterality, and intraoperative stimulation results if performed.
Documentation Required
PNS lead placement — target nerve documentation
PNS trials described specific target nerves; when submitting implant or trial claims, specify the nerve targeted and procedural guidance used in the documentation.
State the anatomic target(s) and provide intraoperative/fluoroscopic images or operative report details.
Include any neurophysiologic testing or stimulation responses observed.
Documentation Required
PEMF for knee OA — radiographic confirmation where applicable
For PEMF in knee OA trials, radiographic confirmation of OA severity (eg, Kellgren‑Lawrence grade I–III) was used for eligibility; include radiographic OA grading when applicable.
Attach knee radiographs and document KL grade if used to support PEMF use for OA.
Provide prior conservative therapy details and outcomes.
Documentation Required
Scrambler therapy for poststroke pain — neuroimaging for stroke confirmation in that trial
In a poststroke scrambler therapy trial, neuroimaging (CT/MRI) was used to confirm stroke diagnosis; include imaging confirmation when the indication is poststroke pain.
Attach neuroimaging confirming stroke if requesting scrambler therapy for poststroke pain.
Document stroke characteristics and timing.
Note
Scrambler therapy — no routine imaging requirement stated
Routine imaging is not required for scrambler therapy per the evidence summaries, but include imaging only when clinically indicated or when used in a supporting study.
Documentation Required
Restorative neurostimulation — imaging or physiologic testing supportive documentation expected
For restorative neurostimulation, the device PMA requires evidence of multifidus dysfunction by imaging or physiologic testing; include such evidence in the authorization documentation.
Provide imaging (eg, MRI) or physiologic testing demonstrating multifidus dysfunction as part of PMA‑aligned documentation.
Document prior conservative therapy failures and specialist evaluation.
Clinical usesRehabilitation after surgery, neurologic injury, and to augment strength/circulation in MSK conditions
inv-126: PENS definition
DefinitionPENS: minimally invasive technique using acupuncture-like needles connected to an external power source inserted percutaneously to treat pain
DistinctionNeedle electrodes penetrate skin (percutaneous) versus cutaneous electrodes (TENS)
Typical protocolsStudies vary from single to multiple sessions (1–16); ultrasound guidance used in some trials
DefinitionPercutaneous PNS: electrode(s) implanted or placed near a peripheral nerve to deliver electrical impulses that disrupt pain signal transmission
Device examplesSystems include StimRouter, SPRINT, Freedom; includes temporary percutaneous and permanent implants
Typical trial durationShort-term trials commonly 60 days prior to assessment/implant decisions
inv-128: Peripheral Nerve Field Stimulation (PNFS)
DefinitionPeripheral Nerve Field Stimulation (PNFS): implantation of electrode arrays in subcutaneous tissue over a painful area when stimulation field is not limited to a single peripheral nerve
Use caseApplied when pain distribution is diffuse or not confined to a named peripheral nerve
EvidenceEvidence limited to small trials and case series; further robust trials needed
inv-129: TENS definition
DefinitionTENS: noninvasive surface electrodes deliver electric current to activate peripheral nerves and reduce pain perception via afferent inhibition or endorphin release
DistinctionTENS targets sensory nerves and is distinct from NMES/FES which elicit muscle contractions
RegulationTENS devices are FDA Class II devices (product codes GZJ, NUH, NGX)
Alternate descriptionFES: electrical stimulation applied to muscles or nerves to produce functional movements or therapeutic effects (used in SCI, CP, stroke, MS)
ModesCan be therapeutic (exercise) or functional (assistive) depending on goal
Outcome targetsStanding, ambulation, grasping, respiratory support, bowel/bladder function
inv-131: Restorative Neurostimulation definition
DefinitionRestorative neurostimulation: implanted stimulation targeting the multifidus via leads near the medial branch to rehabilitate neuromuscular control in chronic mechanical low back pain
Example deviceReActiv8 Implantable Neurostimulation System (PMA-approved for multifidus dysfunction)
Indication contextUsed in patients with refractory mechanical CLBP after failure of conservative therapy
inv-132: Scrambler Therapy definition
DefinitionScrambler therapy: noninvasive transdermal treatment delivering variable nonlinear waveforms via skin electrodes to present nonpain information to a painful area
Typical protocolSessions typically 30–50 minutes over ~10 working days in many trials
Evidence summaryTrials report short-term analgesic effects but overall quality rated low; guideline bodies caution use outside trials
inv-133: PEMF definition
DefinitionPEMF: application of pulsed electromagnetic fields hypothesized to facilitate bone/cartilage repair and alter inflammatory cell function
ParametersStudies report frequencies 3–50 Hz and intensities 1.5–150 mT with varied session durations
Evidence stanceEvidence insufficient to broadly support PEMF for pain; results heterogeneous
inv-134: Translingual Stimulation definition
DefinitionTranslingual stimulation (TLS/PoNS): noninvasive stimulation of trigeminal and facial nerves via tongue device combined with targeted PT to enhance neuroplasticity and motor relearning
Clinical contextsInvestigated for gait and balance in mmTBI, MS, CP; evidence inconclusive
Regulatory/Evidence noteECRI assessment found inconclusive evidence and recommended further trials
inv-135: CCFES definition
DefinitionContralaterally Controlled FES (CCFES): FES in which stimulation to the affected limb is controlled by movement of the contralateral (unaffected) limb
Clinical findingCCFES showed greater improvement than cNMES in pooled RCTs for upper-extremity motor outcomes
Use caseApplied in poststroke upper-extremity rehabilitation trials
inv-136: Assistive vs Rehabilitative FES
DistinctionAssistive FES provides functional assistance during activity (eg, foot-drop device during walking); rehabilitative FES aims for lasting motor recovery through repeated training
Clinical implicationAssistive vs rehabilitative goals influence expected outcomes and trial design
Evidence noteRehabilitative effects less consistently demonstrated long-term in RCTs
inv-137: CCFES (additional citations)
CCFES additional evidenceMeta-analysis (Loh et al.) pooled 6 RCTs showing CCFES superiority on several upper-extremity outcomes vs cyclic NMES
LimitationsLack of blinding, small number of trials, and variability in stroke phase
RecommendationFurther RCTs recommended to confirm efficacy and compare to other modalities
inv-138: NMES (definitions repeated)
NMES summaryNMES evokes muscle contractions to improve circulation, prevent atrophy, augment strength, reduce edema, and assist functional recovery
Evidence characteristicsProtocols heterogeneous; effect sizes vary by indication and timing
inv-139: NMES summary definition
NMES summary definitionNeuromuscular electrical stimulation used to evoke muscle contractions for rehabilitation and prevention of disuse atrophy when nerve supply intact
Outcome examplesImproved quadriceps strength, reduced edema, improved swallowing when combined with therapy
Evidence noteFurther high-quality RCTs needed to standardize parameters and confirm long-term benefit
inv-142: IFT definition
IFT definitionInterferential therapy (IFT): a transcutaneous medium-frequency electrical stimulation modality studied for pain relief in musculoskeletal conditions
Evidence stanceInsufficient evidence to support safety and efficacy for MSK pain, fractures, or soft tissue healing
Protocol variabilityDevices and parameters heterogeneous across trials
inv-143: Interferential therapy (IFT)
IFT descriptionMedium-frequency electrotherapy studied for knee OA, postoperative and soft-tissue MSK conditions; trials report short-term pain/function improvements in some studies
Evidence limitationsHeterogeneity and small trials; NICE guidance recommends against routine use for some indications
MENS/MCT/FSM definitionMicrocurrent electrical nerve stimulation: very low-intensity electrical stimulation intended to modulate pain and facilitate healing
Evidence baseSmall RCTs and nonrandomized studies; pooled analyses limited by heterogeneity and small samples
Typical usesAcute knee pain, shoulder, LBP, wound healing in small studies
inv-145: MENS / MET / FSM
MENS / MET / FSM summaryMicrocurrent therapies deliver low-amplitude currents transcutaneously per defined protocols; limited high-quality evidence exists
Study regimensExamples include daily multi-hour application for several weeks in small RCTs
RecommendationFurther large RCTs needed to establish effectiveness and dosing
Study characteristicsProtocols heterogeneous; some trials use ultrasound guidance; session counts vary widely
Evidence noteQuality generally low to moderate; not recommended as first-line for CLBP per NICE
inv-147: PENFS / auricular neuromodulation
PENFS / auricular devicesPercutaneous electrical nerve field stimulation (auricular) uses small percutaneous leads on the ear (eg, NSS-2 Bridge) applied for days to reduce postoperative pain/opioid use
Typical courseExamples: 5 days of auricular stimulation post-TKA in pilot randomized trials
Evidence limitationSmall pilot studies; further adequately powered RCTs needed
inv-148: PENFS definition (auricular devices)
PENFS definition (auricular)Percutaneous auricular neuromodulation using small leads applied to the ear for days to weeks, investigated for postoperative pain and opioid-sparing effects
Contraindications notedExclusions in trials: chronic opioid dependence, anticoagulation, pacemaker, pregnancy
EvidencePilot RCTs show opioid-sparing and pain reduction but small sample sizes and short follow-up
inv-149: PNS definition (device examples)
PNS device examplesStimRouter, SPRINT, Freedom (formerly StimQ); temporary and permanent systems described
MechanismLeads placed near peripheral nerve deliver impulses to disrupt pain transmission
Outcomes reportedRCTs and case series report clinically meaningful pain reductions in selected populations
Percutaneous PNS descriptionMinimally invasive placement of percutaneous leads to stimulate peripheral nerves for analgesia; trials commonly include temporary 60-day lead periods
Clinical evidenceMulticenter RCTs report responder rates (eg, Goree et al. TKA: 60% >=50% pain relief vs 24% placebo)
Common adverse eventsLead migration and local skin irritation most frequently reported
inv-151: Peripheral nerve field stimulation (PNFS)
PNFS definitionSubcutaneous field stimulation with implanted electrode arrays targeting a localized painful area rather than a named peripheral nerve
Use casesApplied for diffuse or poorly localized pain fields; evidence limited to small trials and case reports
Regulatory noteNo specific FDA approval for many PNFS devices for pain/muscle rehabilitation
inv-152: Pulsed electromagnetic field (PEMF) stimulation definition
PEMF definitionNoninvasive therapy applying pulsed electromagnetic fields to tissues with proposed effects on pain, bone/cartilage repair, and inflammation
Parameters variabilityFrequencies 3–50 Hz, intensities 1.5–150 mT reported across trials
Evidence summaryMixed short-term benefits in OA and nonspecific LBP; insufficient evidence for fracture healing and chronic pain indications
ReActiv8 definitionReActiv8 restorative neurostimulation: implantable system intended to restore multifidus function in mechanical CLBP associated with multifidus dysfunction
IndicationAdults with intractable CLBP and multifidus dysfunction after failed conservative therapy; PMA-approved device (product code QLK)
Trial outcomesRCTs demonstrated significant ODI and NRS improvements at 1 year vs OMM
Scrambler therapy summaryNoninvasive cutaneous neuromodulation delivering changing waveforms via skin electrodes to present nonpain information; trials report short-term analgesia
Typical protocolSessions 30–50 minutes over ~10 working days in many studies
Evidence cautionSystematic reviews rate evidence low/very low; guideline bodies advise against routine use for CIPN outside trials
inv-158: Translingual Stimulation definition
Translingual (PoNS) summaryNonimplantable tongue-based neuromodulation combined with PT to enhance gait/balance; some RCTs show improvement but control arms often improve too
Evidence limitsECRI found inconclusive evidence; multicenter RCTs small and research center–dependent
Clinical contextsInvestigated in mmTBI, MS, and CP for balance/gait rehabilitation
inv-159: TENS definition
TENS definitionTranscutaneous Electrical Nerve Stimulators: noninvasive devices using surface electrodes to decrease pain perception via peripheral nerve activation
Regulatory noteTENS devices regulated as FDA Class II devices (product codes GZJ, NUH, NGX)
Comparator roleOften used as comparator modality in trials of PENS/PENFS/NMES
The policy cross-references these definitions when describing candidate selection, trial durations, and evidence contexts (for example, temporary percutaneous PNS trials of ~60 days vs permanent implanted systems, and FES uses in SCI or post-stroke motor rehabilitation).